Top

Published in:

01-04-2016 | Therapy in Practice

Vemurafenib-induced progression of breast cancer: a case report and review of the literature

Authors: Aleksei V. Novik, Svetlana A. Protsenko, Irina A. Baldueva, Aleksander O. Ivantsov, Tatyana L. Nekhaeva, Zinaida Y. Akhaeva, Grigoriy A. Yanus, Aglaya G. Iyevleva, Evgeny N. Imyanitov

Published in: Targeted Oncology | Issue 2/2016

Abstract

Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–19. doi:10.1056/NEJMoa1002011 CrossRefPubMedPubMedCentral

Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D et al (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314–22. doi:10.1634/theoncologist.2012-0333 CrossRefPubMedPubMedCentral

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–30. doi:10.1038/nature08902 CrossRefPubMedPubMedCentral

Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T et al (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316–21. doi:10.1056/NEJMoa1208958 CrossRefPubMedPubMedCentral

Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E et al (2014) Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov 4:538–45. doi:10.1158/2159-8290.CD-13-1038 CrossRefPubMedPubMedCentral

Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR et al (2014) BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest 124:5074–84. doi:10.1172/jci76539 CrossRefPubMedPubMedCentral

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H et al (2013) BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 31:e448–51. doi:10.1200/jco.2013.50.4118 CrossRefPubMed

Grey A, Cooper A, McNeil C, O’Toole S, Thompson J, Grimison P (2014) Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Intern Med J 44:597–600. doi:10.1111/imj.12415 CrossRefPubMed

Mellema WW, Burgers SA, Smit EF (2015) Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report. Lung Cancer 87:201–3. doi:10.1016/j.lungcan.2014.11.014 CrossRefPubMed

10.

Lacouture ME, O’Reilly K, Rosen N, Solit DB (2012) Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 30:329–30. doi:10.1200/JCO.2011.38.2895 CrossRefPubMed

11.

Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD et al (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375–83. doi:10.1200/JCO.2011.41.1660 CrossRefPubMedPubMedCentral

12.

Weeraratna AT (2012) RAF around the edges--the paradox of BRAF inhibitors. N Engl J Med 366:271–3. doi:10.1056/NEJMe1111636 CrossRefPubMed

13.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS (2013) Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10:390–9. doi:10.1038/nrclinonc.2013.83 CrossRefPubMedPubMedCentral

14.

Cohen PR, Bedikian AY, Kim KB (2013) Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol 6:27–37PubMedPubMedCentral

15.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR et al (2014) COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol 8:250–60. doi:10.1016/j.molonc.2013.11.005 CrossRefPubMed

Title: Vemurafenib-induced progression of breast cancer: a case report and review of the literature
Authors: Aleksei V. Novik
Svetlana A. Protsenko
Irina A. Baldueva
Aleksander O. Ivantsov
Tatyana L. Nekhaeva
Zinaida Y. Akhaeva
Grigoriy A. Yanus
Aglaya G. Iyevleva
Evgeny N. Imyanitov
Publication date: 01-04-2016
Publisher: Springer International Publishing
Published in: Targeted Oncology / Issue 2/2016
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-015-0384-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma

Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer